|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,729,057: Vildagliptin Formulation
U.S. Patent 8,729,057, titled "Formulation of vildagliptin," issued on May 20, 2014, to Novartis AG. The patent claims specific pharmaceutical formulations of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used for treating type 2 diabetes. The core innovation revolves around improving the stability and bioavailability of vildagliptin through the inclusion of specific excipients.
What is the Primary Invention Claimed in U.S. Patent 8,729,057?
The patent claims solid pharmaceutical formulations of vildagliptin. Specifically, it covers compositions comprising:
- Vildagliptin as the active pharmaceutical ingredient.
- An acid-scavenging agent.
- At least one filler.
- At least one disintegrant.
- At least one lubricant.
The patent emphasizes that the acid-scavenging agent is crucial for stabilizing vildagliptin, which is known to be susceptible to degradation in the presence of acidic compounds.
What are the Key Excipients Mentioned and Their Role?
The patent identifies specific excipients and their purported functions:
- Acid-Scavenging Agent: This is a critical component. Examples provided include alkali metal salts of weak acids, such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium acetate, and potassium acetate. The primary role is to neutralize any acidic species present, thereby preventing the degradation of vildagliptin.
- Filler: These are inert substances that add bulk to the tablet. Examples include lactose monohydrate, microcrystalline cellulose, starch, and dicalcium phosphate.
- Disintegrant: These agents facilitate the breakup of the tablet into smaller fragments after administration, promoting drug dissolution. Examples include crospovidone, sodium starch glycolate, and croscarmellose sodium.
- Lubricant: This excipient reduces friction between the tablet and the die wall during compression, preventing sticking. Magnesium stearate and stearic acid are common examples cited.
What are the Specific Claims Covered by the Patent?
U.S. Patent 8,729,057 contains multiple claims detailing the scope of protection. Key claims include:
- Claim 1: A solid pharmaceutical formulation comprising vildagliptin, an acid-scavenging agent selected from the group consisting of alkali metal salts of weak acids, at least one filler, at least one disintegrant, and at least one lubricant.
- Claim 2: The formulation of claim 1, wherein the acid-scavenging agent is selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium acetate, and potassium acetate.
- Claim 3: The formulation of claim 1, wherein the acid-scavenging agent is sodium carbonate.
- Claim 4: The formulation of claim 1, wherein the filler is selected from the group consisting of lactose monohydrate, microcrystalline cellulose, starch, and dicalcium phosphate.
- Claim 5: The formulation of claim 1, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium.
- Claim 6: The formulation of claim 1, wherein the lubricant is magnesium stearate.
- Claim 7: A solid pharmaceutical formulation comprising vildagliptin, sodium carbonate, lactose monohydrate, crospovidone, and magnesium stearate.
- Claim 8: The formulation of claim 7, wherein the formulation is in the form of a tablet.
- Claim 9: A method of preparing a stable pharmaceutical formulation of vildagliptin comprising admixing vildagliptin, an acid-scavenging agent, at least one filler, at least one disintegrant, and at least one lubricant.
These claims provide a tiered approach to protection, with broader claims covering the general composition and more specific claims protecting particular combinations of excipients, including a preferred embodiment.
What is the Stated Problem Addressed by This Patent?
Vildagliptin is known to be susceptible to degradation, particularly in the presence of acidic excipients or residual moisture. This degradation can lead to a decrease in the drug's potency and the formation of impurities, which are undesirable from a pharmaceutical quality and regulatory perspective. The patent asserts that conventional formulations may not adequately protect vildagliptin from degradation. The invention aims to provide a formulation with enhanced stability, ensuring consistent drug quality and therapeutic efficacy over its shelf life.
What is the Patent Expiration Date?
U.S. Patent 8,729,057 has a nominal expiration date of May 20, 2031. However, patent term adjustments and potential extensions due to regulatory review (e.g., Hatch-Waxman Act) can alter the actual market exclusivity period. For generic manufacturers, the effective expiration date, considering any data exclusivity and potential patent challenges, is a critical factor.
What is the Current Patent Landscape for Vildagliptin Formulations?
The patent landscape for vildagliptin formulations is complex, involving multiple patents covering different aspects of the drug's development, including:
- Composition of Matter Patents: These would cover the vildagliptin molecule itself.
- Formulation Patents: Like U.S. Patent 8,729,057, these cover specific combinations of active ingredients and excipients designed to improve stability, bioavailability, or manufacturing processes.
- Method of Use Patents: These patents protect specific therapeutic applications of vildagliptin for particular patient populations or disease stages.
- Polymorph Patents: Different crystalline forms of a drug can have distinct properties and may be separately patented.
Companies seeking to market generic versions of vildagliptin must navigate this landscape, identifying any relevant patents and assessing their validity, enforceability, and expiration. This often involves "Paragraph IV" certifications under the Hatch-Waxman Act, challenging existing patents.
How Does U.S. Patent 8,729,057 Compare to Other Vildagliptin Patents?
While U.S. Patent 8,729,057 focuses on the stabilization of vildagliptin through specific acid-scavenging excipients, other vildagliptin patents may cover:
- Alternative Formulations: Different excipient combinations, dosage forms (e.g., extended-release), or manufacturing processes. For instance, patents might claim specific ratios of excipients or novel granulation techniques.
- Combinations with Other Drugs: Vildagliptin is often co-formulated with other anti-diabetic agents like metformin. Patents covering these fixed-dose combinations would differ significantly.
- Specific Crystal Forms (Polymorphs): U.S. Patent 8,026,235 also held by Novartis AG claims a specific crystalline form of vildagliptin, denoted as Form A, which is described as having good stability and flowability properties. This patent, with an earlier priority date, protects a distinct aspect of the vildagliptin product.
- Manufacturing Processes: Patents may claim particular methods of synthesizing or producing vildagliptin or its formulated products, focusing on efficiency, yield, or purity.
U.S. Patent 8,729,057's distinctiveness lies in its explicit focus on mitigating vildagliptin's acid sensitivity using acid-scavenging agents within solid oral dosage forms. This specificity is key for potential generic challengers to analyze for non-infringement or invalidity.
What are the Potential Implications for Generic Drug Manufacturers?
For generic manufacturers, U.S. Patent 8,729,057 presents several considerations:
- Freedom-to-Operate (FTO) Analysis: A thorough FTO analysis is required to determine if a proposed generic formulation infringes on the claims of this patent. This involves a detailed comparison of the proposed formulation's components and their intended function against the patent's claims.
- Patent Challenges: Generic companies may seek to invalidate this patent through litigation, arguing that the claims are not novel, are obvious in light of prior art, or are otherwise invalid.
- Formulation Development: Generic developers may aim to create formulations that do not use the specific acid-scavenging agents claimed or fall outside the defined scope of the claims. This could involve using alternative excipients with similar stabilizing effects or developing an amorphous form of vildagliptin, if such a form is not covered by other patents and exhibits sufficient stability without acid scavengers.
- Timing of Market Entry: The expiration of this patent, along with other relevant patents, will dictate the earliest possible date for generic market entry. Understanding any patent term extensions or adjustments is crucial for strategic planning.
The existence of patents like 8,729,057 can influence the complexity and cost of bringing a generic version of vildagliptin to market, potentially delaying entry and impacting pricing strategies.
Key Takeaways
- U.S. Patent 8,729,057 protects specific solid pharmaceutical formulations of vildagliptin that include an acid-scavenging agent to enhance stability.
- The patent claims cover compositions with vildagliptin, acid scavengers (e.g., alkali metal salts of weak acids), fillers, disintegrants, and lubricants.
- A key claimed embodiment involves vildagliptin with sodium carbonate, lactose monohydrate, crospovidone, and magnesium stearate.
- The patent's stated purpose is to overcome vildagliptin's susceptibility to acid-catalyzed degradation, improving formulation stability.
- The nominal expiration date is May 20, 2031, but actual market exclusivity may be affected by regulatory factors.
- The patent landscape for vildagliptin is multifaceted, including formulation, polymorph, and method of use patents, requiring careful navigation for generic entry.
- Generic manufacturers must conduct thorough freedom-to-operate analyses, consider patent challenges, and develop alternative formulations to potentially circumvent this patent's scope.
Frequently Asked Questions
1. What is the primary technical innovation claimed by U.S. Patent 8,729,057?
The primary innovation is a solid pharmaceutical formulation of vildagliptin that includes an acid-scavenging agent to stabilize the drug against degradation, which is particularly sensitive to acidic environments.
2. Are there any specific percentages or ratios of excipients defined in the patent claims?
The patent claims define the presence of the components but do not specify exact percentage ranges or ratios for most excipients, focusing on the presence and function of the acid-scavenging agent. Claim 7, however, specifies a composition without precise ratios.
3. What is the difference between this patent and patents covering the vildagliptin molecule itself?
This patent focuses on a specific formulation of vildagliptin, meaning the combination of ingredients and their arrangement in a dosage form. Patents covering the molecule itself (composition of matter) protect the chemical entity vildagliptin regardless of how it is formulated.
4. Can a generic company use vildagliptin without infringing this patent?
A generic company can use vildagliptin without infringing this patent if their formulation does not include the specific combination of vildagliptin and the claimed excipients, particularly the acid-scavenging agent, or if they can demonstrate that the claimed formulation is invalid or that their product falls outside the scope of the patent's claims.
5. Does this patent protect against all possible formulations of vildagliptin?
No, this patent specifically protects the claimed solid pharmaceutical formulations containing vildagliptin and an acid-scavenging agent. Other formulations, such as those using different excipients, different dosage forms (e.g., liquid, extended-release), or different stabilizing mechanisms, might not be covered by this patent.
Citations
[1] Novartis AG. (2014). U.S. Patent 8,729,057: Formulation of vildagliptin. United States Patent and Trademark Office.
[2] Novartis AG. (2012). U.S. Patent 8,026,235: Crystalline form of vildagliptin. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
